AIGH Capital Management LLC recently announced the acquisition of new stake in Cellectar Biosciences Inc (NASDAQ:CLRB). The institutional investor has increased its shareholding in the Healthcare company by 182.68% to 1.92 million shares with purchase of 1.24 million shares. This fresh investment now brings its stake to 9.93% valued currently at $4.73 million. In addition, Acuta Capital Partners LLC raised its holdings by 0.12 million to 0.12 million shares. And The Vanguard Group, Inc. has lifted its position by 2.30% or 3911.0 shares – to 0.17 million shares.
With over 30.88 million Cellectar Biosciences Inc (CLRB) shares trading Monday and a closing price of $3.20 on the day, the dollar volume was approximately $98.83 million. The shares have shown a positive half year performance of 78.27% and its price on 01/08/24 gained nearly 18.08%. Currently, there are 12.29M common shares owned by the public and among those 11.01M shares have been available to trade.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Insiders at the company have transacted a total of 0 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 0 of these insider trades were purchases, accounting for 0 shares. Insider sales of the common stock occurred on 0 occasions, with total insider shares sold totaling 0 shares.
The top 3 mutual fund holders in Cellectar Biosciences Inc are Vanguard Total Stock Market ETF, Vanguard Extended Market Index Fu, and Fidelity Extended Market Index Fu. Vanguard Total Stock Market ETF owns 99704.0 shares of the company’s stock, all valued at over $0.25 million. Fidelity Extended Market Index Fu now owns shares totaling to 0.21% of the shares outstanding.
Shares of Cellectar Biosciences Inc (NASDAQ: CLRB) opened at $3.12, up $0.41 from a prior closing price of $2.71. The company’s stock has a 5-day price change of 15.52% and 10.34% over the past three months. CLRB shares are trading 15.52% year to date (YTD), with the 12-month market performance up to 90.48% higher. It has a 12-month low price of $1.30 and touched a high of $3.20 over the same period. CLRB has an average intraday trading volume of 316.15K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 20.69%, 31.84%, and 59.03% respectively.
Institutional ownership of Cellectar Biosciences Inc (NASDAQ: CLRB) shares accounts for 29.97% of the company’s 12.29M shares outstanding. Mutual fund holders own 1.30%, while other institutional holders and individual stakeholders account for 18.18% and 1.26% respectively.
It has a market capitalization of $39.33M and a beta (3y monthly) value of 0.93. The earnings-per-share (ttm) stands at -$3.48. Price movements for the stock have been influenced by the stock’s volatility, which stands at 14.83% over the week and 9.97% over the month.
Analysts forecast that Cellectar Biosciences Inc (CLRB) will achieve an EPS of -$1 for the current quarter, -$0.72 for the next quarter and -$2.83 for 2023. The lowest estimate earnings-per-share for the quarter is -$1.43 while analysts give the company a high EPS estimate of -$0.69. Comparatively, EPS for the current quarter was -$0.9 a year ago. Earnings per share for the fiscal year are expected to increase by 40.43%, and 26.22% over the next financial year.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 4 brokerage firm advisors rate Cellectar Biosciences Inc (CLRB) as a “Strong Buy” at a consensus score of 1.00. Specifically, 4 Wall Street analysts polled rate the stock as a buy, while 0 of the 4 advise that investors “hold,” and 0 rated it as a “Sell.”
